Results 91 to 100 of about 4,115 (133)

miR-590-5P inhibits the progression of tongue squamous cell carcinoma by targeting FasL.

open access: yesInternational journal of clinical and experimental pathology
This study evaluated microRNA-590-5P (miR-590-5P), which functions as an anti-onco-miRNA in TSCC by downregulating FasL expression.In this study, immunohistochemistry was used to detect FasL protein expression in 30 OSCC samples and 8 normal oral mucosa tissue samples. Target Scan was used to predict miRNAs that target FasL.
Yanxue, Xu   +3 more
openaire   +1 more source

The Practical Landscape of Cytokine‐Targeted miRNAs to Enhance NK Cell Function in Cancer Immunotherapy: A Bioinformatic Analysis

open access: yesCancer Reports
Introduction Suppression within the tumor microenvironment (TME) hampered natural killer (NK) cells and their role in cancer immunotherapy. This study explores how interleukin (IL) signaling (IL‐12A, IL‐12B, IL‐15, IL‐18) and interferon gamma (IFNG or ...
Arefeh Zabeti Touchaei   +2 more
doaj   +1 more source

miR-590-5p promotes liver cancer growth and chemotherapy resistance through directly targeting FOXO1.

open access: yesAmerican journal of translational research
miR-590-5p functions as an onco-miR or an anti-onco-miR in various types of cancers. However, the exact role of miR-590-5p in liver cancer remains to be elucidated. In the present study, we explored the predictive role of miR-590-5p expression in liver cancer patients.
Guiqing, Jia   +6 more
openaire   +1 more source

miR-590-5p affects chondrocyte proliferation, apoptosis, and inflammation by targeting FGF18 in osteoarthritis.

open access: yesAmerican journal of translational research
To investigate the potential miRNA targeting FGF18, and its role in regulating the proliferation, apoptosis and inflammation in human primary chondrocytes.The normal human chondrocytes were induced by IL-1β to mimic OA in vitro. qPCR and Western blotting were performed to evaluate the expression of FGF18.
Peng, Jiang   +7 more
openaire   +1 more source

Home - About - Disclaimer - Privacy